Heron Therapeutics, Inc.

NASDAQ:HRTX

Biotechnology

Healthcare
$0.26 +3.74%

+$0.01 today

Market cap
$50.25M
Beta
1.57
P/E (TTM)
-2.5
EPS (TTM)
-$0.16
52W Low $0.38High $2.30

Volume 3.60M

Average 2.90M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$27.59M

FY 2025 · Annual

Investing Cash Flow

$16.01M

FY 2025 · Annual

-14.5% YoY

Financing Cash Flow

$14.43M

FY 2025 · Annual

+1434.8% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(220.68M)(182.02M)(110.56M)(13.58M)(20.2M)
Depreciation & Amortization3.02M2.89M2.9M2.49M2.31M
Deferred Income Tax1.63M0000
Stock-Based Compensation46.85M42.98M32.85M12.96M10.34M
Change in Working Capital(35.08M)(10.51M)16.79M(27.6M)(31.88M)
Accounts Receivables6.35M(16.55M)(8.09M)(18.74M)(10.71M)
Inventory(6.48M)(6.19M)12.46M(11.05M)(31.05M)
Accounts Payables3.28M(578K)15K8.47M(2.72M)
Other Working Capital(38.23M)12.81M12.4M(6.28M)12.59M
Other Non-Cash Items904K(251K)(773K)3.2M11.83M
Operating Cash Flow(203.35M)(146.91M)(58.79M)(22.53M)(27.59M)
Capital Expenditures(3.02M)(1.83M)(1.55M)(1.71M)(317K)
Acquisitions (Net)32K227K13K27K0
Purchases of Investments(129.22M)(145.68M)(87.66M)(103.09M)(50.79M)
Sales of Investments164.94M143.96M107.19M123.48M67.01M
Other Investing Activities000098K
Investing Cash Flow32.73M(3.32M)18M18.71M16.01M
Debt Repayment148.96M024.35M0145.11M
Common Stock Issued7.07M75.06M29.76M940K19.32M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0000(150M)
Financing Cash Flow156.03M75.06M54.11M940K14.43M
Effect of Forex Changes00000
Net Change in Cash(14.6M)(75.18M)13.31M(2.88M)2.85M
Free Cash Flow(206.38M)(148.74M)(60.33M)(24.24M)(27.91M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$20.2M
+ D&A$2.3M
+ Stock-Based Comp$10.3M
+ Deferred Tax$0
- Working Capital-$31.9M
+ Other Non-Cash$11.8M
= Operating Cash Flow-$27.6M
- Capex-$317.0K
= Free Cash Flow-$27.9M

Analysis

FY2025 free cash flow is -$27.9M. FCF conversion is 138.2% of net income. Operating cash flow was -$27.6M, with capex of -$317.0K. The largest bridge item is Working Capital at -$31.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 10, 2026
8-KCurrent reportNov 9, 2026
8-KCurrent reportNov 9, 2026
DEFA14ADEFA14A filingNov 9, 2026
DEFA14ADEFA14A filingNov 9, 2026

Does HRTX generate free cash flow?

Heron Therapeutics, Inc. (HRTX) generated -$27.91M of free cash flow in fiscal 2025.

How much operating cash flow does HRTX produce?

Operating cash flow was -$27.59M, before capital expenditures of $317,000.00.